🇺🇸 FDA
Company

Mereo

Mereo BioPharma Group plc

MREO biotech USA

Quick answer

Mereo is a biotech company (MREO) headquartered in LONDON, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Setrusumab

Osteogenesis Imperfecta

Phase 3 · mab · active

2 trials project

Active treatment with a high dose of BGS649

Endometriosis

Phase 2 · small_molecule · completed

1 trials project

Alvelestat

Covid19

Phase 2 · small_molecule · completed

1 trials project

Alvelestat (MPH966)

Alpha-1 Antitrypsin Deficiency (AATD)

Phase 2 · small_molecule · completed

1 trials project

BCT197

Chronic Obstructive Pulmonary Disease

Phase 2 · small_molecule · completed

1 trials project

BCT197

Pulmonary Disease, Chronic Obstructive

Phase 2 · small_molecule · completed

1 trials project

BCT197 Part A

Acute Kidney Injury

Phase 2 · small_molecule · terminated

1 trials project

BGS649

Hypogonadotropic Hypogonadism

Phase 2 · small_molecule · completed

2 trials project

BGS649

Pelvic Pain Associated With Refractory Endometriosis

Phase 2 · small_molecule · terminated

1 trials project

BPS804

Chronic-kidney Disease Stage 5D on Stable Hemodialysis

Phase 2 · small_molecule · terminated

1 trials project

BPS804

Hypophosphatasia

Phase 2 · small_molecule · completed

1 trials project

BPS804

Osteogenesis Imperfecta

Phase 2 · small_molecule · terminated

1 trials project

BPS804 20mg/Kg

Osteopenia

Phase 2 · small_molecule · completed

1 trials project

Demcizumab

Pancreatic Cancer

Phase 2 · small_molecule · completed

2 trials project

Etigilimab

Solid Tumor, Adult

Phase 2 · small_molecule · completed

1 trials project

Investigational new drug company code: BGS649

Obese Hypogonadotropic Hypogonadism

Phase 2 · small_molecule · terminated

1 trials project

MPH966

Hematologic Malignancy

Phase 2 · small_molecule · terminated

1 trials project

Nivolumab

Ovarian Cancer

Phase 2 · small_molecule · active

1 trials project

OMP-59R5

Stage IV Pancreatic Cancer

Phase 2 · small_molecule · completed

1 trials project

OMP-59R5

Stage IV Small Cell Lung Cancer

Phase 2 · small_molecule · terminated

1 trials project

Pemetrexed

Nonsquamous Nonsmall Cell Neoplasm of Lung

Phase 2 · small_molecule · completed

1 trials project

Placebo Oral Tablet

Alpha 1-Antitrypsin Deficiency

Phase 2 · small_molecule · completed

1 trials project

setrusumab

Osteogenesis Imperfecta, Type I

Phase 2 · small_molecule · completed

1 trials project

BCT197

Interaction

Phase 1 · small_molecule · completed

2 trials

Patents (8)

patent

US 12173058

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11701341

Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzami

Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11512128

VEGF/DLL4 binding agents and uses thereof

Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11434204

Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol

Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11339213

Methods and compositions for treatment of cancer

Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11234967

Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzami

Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11230596

Methods for treatment of cancer comprising TIGIT-binding agents

Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11136384

Methods for treatment of cancer comprising TIGIT-binding agents

Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)